Protective effect of captopril against cisplatin-induced nephrotoxicity in rats

Pakistan Journal of Pharmaceutical Sciences

Volumn 21, Issue 3, 2008, Pages 255-261

  El Sayed, El Sayed M ^a   Abd Ellah, Mohamed F ^a   Attia, Sabry M ^a  

^a Cairo University   (Egypt)

Author keywords

Captopril; Cisplatin; Endothelin; Glutathione; Malondialdehyde; Nitric oxide

Indexed keywords

CAPTOPRIL; CISPLATIN; CREATININE; ENDOTHELIN 1; GLUTATHIONE; LIPID PEROXIDE; MALONALDEHYDE; NITRIC OXIDE; SCAVENGER; THIOL DERIVATIVE; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG INDUCED DISEASE; HYPERTENSION; KIDNEY; KIDNEY INJURY; MALE; NEPHROTOXICITY; NONHUMAN; RAT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; KIDNEY DISEASE; LIPID PEROXIDATION; METABOLISM; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CAPTOPRIL; CISPLATIN; CREATININE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FREE RADICAL SCAVENGERS; GLUTATHIONE; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; MALE; NITRIC OXIDE; RATS; RATS, WISTAR;

EID: 55249094911     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Al-Majed AA, Abd-Allah AR, Al-Rikabi AC, Al-Shabanah OA, Mostafa AM (2003). Effect of oral administration of Arabic gum on cisplatin-induced nephrotoxicity in rats. J. Biochem. Mol. Toxicol., 17(3): 146-153. (Pubitemid 36818189)
2. Baliga R, Zhang Z, Baliga M (1998). In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int., 53: 394-400. (Pubitemid 28097855)
3. Beckman JS and Koppenol WH (1996). Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am. J. Physiol., 271: C1424-C1437.
4. Behling EB, Sendao MC, Francescato HDC, Antunes LMG, Costa RS and Bianchi MP (2006). Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol. Rep., 58: 526-532.
5. Belvisi MG, Stretton CD and Barnes PJ (1992). Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur. J. Pharmacol., 210(2): 221-222,
6. Beutler E, Duran O and Kelly BM (1963). Improved method of determination of blood glutathione. J. Lab. Clin. Med., 61(5): 852-855.
7. Bompart G (1989). Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug metabolizing enzyme activities in rat kidney cortex. Toxicol. Lett., 48(2): 193-199. (Pubitemid 19213429)
8. Bonini MG and Augusto O (2001). Carbon dioxide stimulates the production of thiyl, sulfinyl, and disulfide radical anion from thiol oxidation by peroxynitrite. J. Biol. Chem., 276(13): 9749-9754.
9. Bonsenes RW and Taussky HN (1945). On the colorimetric determination of creatinine by the Jaffe Reaction. J. Biol. Chem., 158: 587-591.
10. 2+ concentration on endothelin-1 secretion. FEBS Lett., 350: 33-36.
11. Bruzzi I, Remuzzi G and Benigni A (1997). Endothelin: a mediator of renal disease progression. J. Nephrol., 10: 179-183. (Pubitemid 27333192)
12. Cetin R, devrim E, Kilicogula B, Avci A, Candir O and Durak I (2006). Cisplatin impairs antioxidant system and causes oxidation in rat kidney tissues: possible protective roles of natural antioxidant foods. J. Appl. Toxicol., 26(1): 42-46.
13. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE and McMurray J (1992). Antioxidant effects of angiotensin-converting (ACE) inhibitors: free radical and antioxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol., 19: 330-340.
14. Cubeddu LX, Lindley CM, Wetsel W, Carl PL and Negro-Vilar A (1990). Role of angiotensin II and vasopressin in cisplatin-induced emesis. Life Sci., 46(10): 699-705. (Pubitemid 20087872)
15. deCavanagh EM, Inserra F, Ferder L and Fraga CG (2000). Enalapril and captopril enhance glutathione-dependent antioxidant defence in mouse tissues. Am. J. Physiol. Regul. Integr. Comp. Physiol., 278: R572-R577.
16. deCavanagh EM, Fraga CG, Ferder L and Inserra F (1997). Enalapril and captopril enhance antioxidant defenses in mouse tissues. Am. J. Physiol. Regul. Integr. Comp. Physiol., 272: R514-R518.
17. deCavanagh EM, Inserra F, Ferder L, Romano L, Ercole L and Fraga CG (1995). Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver. FEBS Lett., 361: 22-24.
18. Deng G, Vaziri ND, Jabbari B, Ni Z and Yan XX (2001). Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J. Am. Soc. Nephrol., 12: 1892-1899. (Pubitemid 32801364)
19. Garg UC and Hassid A (1990). Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem. Biophys. Res. Commun., 171(1): 474-479.
20. Garnick MB, Mayer RJ and Abelson HT (1988). Acute renal failure associated with cancer treatment. In: Acute renal failure. Eds.: Brenner B.M., Lazarus J.M., Churchill Livingstone, New York, pp.621-657.
21. Goligorsky MS, Brodsky AV and Noiri E (2002). Nitric oxide in acute renal failure: NOS versus NOS. Kidney Int., 61: 855-861.
22. Gossmann J, Radounikli A, Bernemann A, Schellinski O, Raab HP and Bickeboller R (2001). Pathophysiology of cyclosporine-induced nephrotoxicity in humans: a role for nitric oxide. Kidney Blood Press. Res., 24: 111-115. (Pubitemid 32642064)
23. Guo FH, DeRaeve HR, Rice TW, Stuehr DJ, Thunnissen FB and Erzurum SC (1995). Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. USA, 92(17): 7809-7813.
24. Hallet CJ and Cook JG (1971). Reduced nicotinamide adenine dinucleotide-coupled reaction for emergency blood urea estimation. Clin. Chim. Acta, 35: 33-37.
25. nd ed.), Oxford, UK, Clarendon, pp.87-187.
26. Hogg N and Kalyanaraman B (1999). Nitric oxide and lipid peroxidation. Biochim. Biophys. Acta, 1411: 378-384.
27. Ignarro L, Buga G and Wood K (1987). Endothelium-derived relaxing factor produced and released from artery and veins is nitric oxide. Proc. Natl. Acad. Sci., USA, 84: 9265-9268.
28. Jones MM, Basinger MA and Holscher MA (1992). Control of nephrotoxicity of cisplatin by clinically used sulfur-containing compounds. Fundam. Appl. Toxicol., 18: 181-188.
29. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ and Jones OT (1996). Expression of phagocyte NADPH oxidase components in human endothelial cells. Am. J. Physiol., 271: H1626-H1634. (Pubitemid 126833722)
30. Kadikoylu G, Bolaman Z, Demir S, Balkaya M, Akalin N and Enli Y (2004). The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys. Hum. Exp. Toxicol., 23(1): 29-34. (Pubitemid 38263155)
31. Kalia K, Narula GD, Kannan GM and Flora SJ (2007). Effects of combined administration of captopril and DMSA on arsenite induced oxidative stress and blood and tissue arsenic concentration in rats. Comp. Biochem. Physiol. C. Toxicol. Pharmacol., 144(4): 372-379. (Pubitemid 46178557)
32. Knotek M, Jaksic O, Selmani R, Skoric B and Banfic H (1996). Different endothelin receptor subtypes are involved in phospholipid signalling in the proximal tubule of rat kidney. Pflugers Arch., 432: 165-173. (Pubitemid 26226097)
33. Kuhlmann MK, Burkhardt G and Köhler H (1997). Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant., 12(12): 2478-2480. (Pubitemid 27520658)
34. Lapointe N, Blais C, Adam A, Parker T, Sirois MG, Gosselin H, Clément R and Rouleau JL (2002). Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat. J. Am. Coll. Cardiol., 39(10): 1692-1698. (Pubitemid 34494295)
35. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA and Haskins JR (1995). Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int., 48(3): 761-770.
36. Mansour HH, Hafez HF and Fahmy NM (2006). Silymarin modulates cisplatin-induced oxidative stress and hepatotoxicity in rats. J. Biochem. Mol. Biol., 39(6): 656-661. (Pubitemid 44892889)
37. Mansour MA, El-Kashef HA and Al-Shabanah OA (1999). Effect of captopril on doxorubicin-induced nephrotoxicity in normal rats. Pharmacol. Res., 39(3): 233-237. (Pubitemid 29119030)
38. Marvaala EMA, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, Müller DN, Fiebeler A, Ganten U, Ganten D and Luft FC (2001). Endothelial dysfunction and Xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension, 37(2): 414-422. (Pubitemid 32199003)
39. Masereeuw R, Terlouw SA, vanAubel RAMH, Russel FGM and Miller DS (2000). Endothlin B receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol. Pharm., 57: 59-67.
40. Matsushima H, Yonemura K, Ohishi K and Hishida A (1998). The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med., 131: 518-526. (Pubitemid 28278570)
41. Meyer KB and Medias NE (1994). Cisplatin nephrotoxicity. Minor Electrolyte Metab., 20: 201-213.
42. Miyaji T, Kato A, Yasuda H, Fujigaki Y and Hishida A (2001). Role of the increase in p21 in cisplatin-induced acute renal failure in rats. J. Am. Soc. Nephrol., 12: 900-908. (Pubitemid 32378330)
43. Murphy MP (1999). Nitric oxide and cell death. Biochim. Biophys. Acta, 1411: 401-414.
44. Omata K, Kanazawa M, Sato T, Abe F, Saito T and Abe K (1996). Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int., 49(S 55): S57-S62. (Pubitemid 26000745)
45. Peresleni T, Noiri E, Bahou WF and Goligorsky MS (1996). Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Am. J. Physiol., 270: F971-F977. (Pubitemid 26298646)
46. Pfeiffer S, Schmidt K and Mayer B (200). Dityrosine formation outcompetes nitration at low steady-state concentrations of peroxynitrite. Implications for tyrosine modification by nitric oxide/superoxide in vivo. J. Biol. Chem., 275(9): 6346-6352.
47. Radi R, Beckman JS, Bush KM and Freeman BA (1991). Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys., 288(2): 481-487.
48. Rosenberg JM and Sato PH (1993). Cisplatin inhibits in vitro translation by preventing the formation of complete initiation complex. Mol. Pharmacol., 43(3): 491-497.
49. Ruschitzka F, Shaw S, Gygi D, Noll G, Barton M and Luscher TF (1999). Endothelial dysfunction in acute renal failure: role of circulating and tissue endothelin-1. J. Am. Soc. Nephrol., 10: 953-962. (Pubitemid 29203081)
50. Salahudeen A, Poovala V, Parry W, Pande R, Kanji V, Ansari N, Morrow J and Roberts J (1998). Cisplatin induced N-acetyl cysteine suppressible F2-isoprostane production and injury in renal tubular epithelial cells. J. Am. Soc. Nephrol., 9(8): 1448-1455. (Pubitemid 28354555)
51. Schwarz PM, Kleinert H and Förstermann U (1999). Potential functional significance of brain-type and muscle-type nitric oxide synthase I expressed in adventitia and media of rat aorta. Arteriscler. Thromb. Vasc. Biol., 19(11): 2584-2590. (Pubitemid 29536031)
52. Taguchi T, Nazneen A, Abid MR and Razzaque MS (2995). Cisplatin-associated nephrotoxicity and pathological events. Contrib. Nephrol., 148: 107-121.
53. Takeda M, Komeyama T, Tsutsui T, Mizusawa T, Go H, Hatano A and Tanikawa T (1994). Changes in urinary excretion of endothelin-1-like immunoreactivity in patients with testicular cancer receiving high-dose cisplatin therapy. Am. J. Kidney Dis., 24(1): 12-16. (Pubitemid 24212971)
54. Townsend DM, Deng M, Zhang L, Lapus MG and Hangian MH (2003). Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J. Am. Soc. Nephrol., 14(1): 1-10. (Pubitemid 36026291)
55. Turpaev KT (1998). Nitric oxide in intercellular communication. Mol. Biol., 32: 475-484.
56. Uehara T, Watanable H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J and Maruyama T (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch. Toxicol., 79(8): 451-460. (Pubitemid 41191383)
57. Van Gilst WH, deGraeff PA, Wesseling H and deLangen CDJ (1986). Reduction of reperfusion arrhythmias in the ischemic isolated heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE 498. Cardiovasc. Pharmacol., 8: 722-728.
58. Weichert-Jacobsen KJ, Bannowski A, Kuppers F, Loch T and Stöckle M (1999). Direct amifostine effect on renal tubule cells in rats. Cancer Res., 59: 3451-3453. (Pubitemid 29334507)
59. Weiner MW and Jacobs C (1983). Mechanism of cisplatin nephrotoxicity. Fed. Proc., 42: 2974-2978.
60. 2 kinin receptor knockout mice. Circ. Res., 88: 1072-1079.
61. Yoshioka T, Kawada K, Shimada T and Mori M (1979). Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am. J. Obstet. Gynecol., 135: 372-376. (Pubitemid 9253643)
62. Zhang JG and Lindup WE (1993). Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem. Pharmacol.,45(11): 2215-2222.